Avant Diagnostics to Attend 12th Annual Noble Capital Markets Conference

SCOTTSDALE, Ariz., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. (OTCQB:AVDX), "Avant", announces that CEO Gregg Linn will be presenting at the NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference at in Sandpiper Bay, Florida, on Tuesday, January 19, 2016 at 2:00PM  Eastern Standard Time.

Following the Conference on January 22, 2016, a high-definition video webcast of Avant Diagnostics, presentation and a copy of the presentation materials will be available on the Avant's website www.avantdiagnostics.com, or as part of a complete catalog of presentations available at Noble Financial websites: www.noblefcm.com, or www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

About Avant Diagnostics, Inc.

Avant is a medical diagnostic technology company that specializes in large panel biomarker tests. Our first test, OvaDx®, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx®indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx®. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.

About Noble Financial Capital Markets

Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous “non-deal” corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB.www.noblefcm.com

Safe Harbor Statement

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant's Form 8-K filed with the Securities and Exchange Commission on January 14, 2015, as amended on January 16, 2015, and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Avant Diagnostics
Gregg Linn
602-524-4165
President/CEO
[email protected]
www.avantdiagnostics.com

Or

Goal Capital Inc., Investor Relations 
Danny Gravelle 
Tel 949-305-5093 
[email protected]